Implementation Science Study Evaluating the Real‐World Use of Blood‐Based Biomarkers as Confirmatory Diagnostic Tools for Alzheimer's Disease in the United States
Findings will provide insights into the feasibility of and potential barriers to implementing confirmatory BBMs into routine care. Evaluating the use of BBMs in real-world settings may lead to efficient implementation at the population level, simplifying the AD patient care pathway by providing clinicians with a minimally invasive and non-ionizing diagnostic for AD.
Authors
- Soeren Mattke (ORCID: https://orcid.org/0000-0003-4666-9132)
- Feride Frech (ORCID: https://orcid.org/0000-0002-1992-1112)
- Christine Divers
- Leah L. Zullig (ORCID: https://orcid.org/0000-0002-6638-409X)
- Daryl Jones
- Jo Vandercappellen (ORCID: https://orcid.org/0000-0001-8073-5493)
- Michelle M. Mielke (ORCID: https://orcid.org/0000-0001-7177-1185)
- Hideki Toyosaki
- Nicholas Giordano
- Douglas R. Galasko
- Harald Hampel
- Marwan N. Sabbagh
Institutions
- University of Southern California (US)
- Barrow Neurological Institute (US)
- Duke University (US)
- Alzheimer’s Disease Neuroimaging Initiative (US)
- Eisai (United States) (US)
- Premier Research Group (US)
- Wake Forest University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099804
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00